- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Mural Oncology, Inc.: Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 09.04. | Mural Oncology, Inc.: Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting | 32 | GlobeNewswire (Europe) | For the first time, the company shares data for its preclinical IL-18 and IL-12 programs-candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance... ► Artikel lesen | |
| 04.04. | Mural Oncology, Inc.: Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 88 | GlobeNewswire (Europe) | WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation... ► Artikel lesen | |
| 26.03. | Mural Oncology plc - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Mural Oncology plc GAAP EPS of -$3.57 | 2 | Seeking Alpha | ||
| 26.03. | Mural Oncology plc - 8-K, Current Report | 3 | SEC Filings | ||
| 26.03. | Mural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update | 137 | GlobeNewswire (Europe) | Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in... ► Artikel lesen | |
| 05.03. | Mural Oncology, Inc.: Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 04.03. | Mural Oncology, Inc.: Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 151 | GlobeNewswire (Europe) | DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein... ► Artikel lesen | |
| 05.02. | Mural Oncology, Inc.: Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 167 | GlobeNewswire (Europe) | DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein... ► Artikel lesen | |
| 16.01. | Mural Oncology plc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 08.01. | Mural Oncology plc - 8-K, Current Report | - | SEC Filings | ||
| 14.12.23 | Mural Oncology plc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.11.23 | Why Is Mural Oncology (MURA) Stock Up 59% Today? | 4 | InvestorPlace | ||
| 17.11.23 | Pre-market Movers: Safe and Green Development, Mural Oncology, Syntec Optics, ChargePoint, Alpha Technology Group | 813 | AFX News | SANTA CLARA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.49 A.M. ET).In the Green Safe and Green Development Corporation (SGD) is... ► Artikel lesen | |
| 15.11.23 | Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout | 8 | FierceBiotech | ||
| 15.11.23 | Mural Oncology plc - 8-K, Current Report | 1 | SEC Filings | ||
| 15.11.23 | Alkermes plc: Alkermes Completes Separation of Oncology Business into Mural Oncology plc | 895 | PR Newswire | - Alkermes Emerges as Pure-Play, Profitable Neuroscience Company -
- Alkermes Provides Updated Financial Expectations for 2023 -
DUBLIN, Nov. 15, 2023 /PRNewswire/ -- Alkermes... ► Artikel lesen | |
| 13.11.23 | Mural Oncology plc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 31.10.23 | Alkermes plc: Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement | 814 | PR Newswire | DUBLIN, Oct. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology)... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 50,55 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting | ||
| BLUEBIRD BIO | 0,887 | +1,53 % | bluebird bio receives non-compliance notice from Nasdaq | ||
| AFFIMED | 4,620 | -1,70 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology | The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | 0,220 | 0,00 % | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento Therapeutics to its Stockholders as a Dividend | PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid... ► Artikel lesen | |
| DENALI THERAPEUTICS | 14,300 | -0,69 % | Biotech-Hoffnung Denali explodiert 38 Prozent: So sind Sie jetzt bei den Top-Trends der Branche ... | Mit einem Kursplus von 38 Prozent hat sich die Aktie des Biotech-Unternehmens Denali Therapeutics am Dienstag eindrucksvoll zurückgemeldet. Der Grund für den Kurssprung sind allerdings nicht Studiendaten... ► Artikel lesen | |
| FATE THERAPEUTICS | 3,600 | +1,49 % | Fate Therapeutics, Inc.: Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting | Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory... ► Artikel lesen | |
| CELLECTIS | 2,340 | 0,00 % | Cellectis S.A. - 6-K, Report of foreign issuer | ||
| AGIOS | 29,400 | 0,00 % | Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights | - Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia - - Presented Positive Results from Phase 2 Portion of... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 7,215 | +1,26 % | Voyager Therapeutics, Inc.: Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting | ||
| UNIQURE | 4,227 | -0,28 % | uniQure Inc.: uniQure Announces 2023 Financial Results and Highlights Recent Company Progress | ~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions... ► Artikel lesen | |
| ENZO BIOCHEM | 0,995 | +1,02 % | Enzo Biochem, Inc.: Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update | FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the second quarter ended January 31, 2024. Second... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,880 | +0,88 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma | ||
| NUVATION BIO | 2,675 | +1,90 % | Nuvation Bio Completes Acquisition of AnHeart Therapeutics | NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and... ► Artikel lesen | |
| 2SEVENTY BIO | 4,255 | -0,82 % | 2seventy bio, Inc. - 8-K, Current Report | ||
| AVROBIO | 1,210 | +2,11 % | AVROBIO and Tectonic Therapeutic Announce Merger | CAMBRIDGE, Mass. & WATERTOWN, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein... ► Artikel lesen |
Das Unternehmen MURAL ONCOLOGY PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,580 Euro und damit +1,42 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
